Inside Information: Faron Announces Encouraging First Overall Survival Data from Frontline Higher-Risk (HR) MDS Patients in the BEXMAB Phase 1/2 Trial

Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients. For patients with biallelic …